Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.09.10.675396

A Human Neuronal Co-Culture System Reveals Early Tumor-Neuron Communication and Targetable Pathways in Glioblastoma

Abstract

BackgroundGlioblastoma (GB, IDH wild type) is the most aggressive primary brain tumor in adults, with recurrence driven by residual tumor cells that re-establish interaction with surrounding neurons. While neuronal activity is recognized as a driver of GB progression, the earliest neuronal responses to tumor contact remain poorly understood. Existing models rarely capture these acute events or the heterogeneity of responses generated by tumors of different origins, limiting insight into the earliest neuron-tumor interactions. MethodsWe developed a dual-interface human iPSC-derived neuronal culture system to investigate acute neuronal responses to glioblastoma exposure. Neurons were challenged with either established GB cell lines or patient-derived glioblastoma cells (PDGCs). Using quantitative proteomics, high-resolution imaging, and immunological assays, we characterized compartment-specific neuronal changes and mapped activated signaling pathways. We also screened selective inhibitors for their effects on both tumor proliferation and neuronal integrity. FindingsWithin 24 hours of exposure, neurons displayed synaptic remodeling and activation of GB-related signaling cascades. Proteomic analysis of GB exposed neurons revealed enrichment of pathways associated with GB and abnormalities in neuronal circuits. Notably, the U-87MG cell line, but not PDGCs, induced pronounced synaptic disruption, neurite retraction, and MAPK pathway activation, with distinct molecular signatures across neuronal compartments. ERK1/2 and p38 MAPK signaling were differentially activated depending on the GB cells source, correlating with specific structural and functional synaptic alterations. Targeted inhibition of MAPK components significantly suppressed U-87MG proliferation and preserved neuronal architecture. InterpretationWe present a human neuronal culture model that detects and discriminates the earliest neuron-derived responses to glioblastoma from diverse tumor sources. By linking neuronal remodeling to tumor-specific signaling pathways, the platform uncovers both the heterogeneity of neuron-tumor interactions and early, targetable vulnerabilities. This system offers a translational tool to advance understanding of GB recurrence and to guide development of therapies with dual neuroprotective and anti-tumor efficacy. In BriefEarly interactions between glioblastoma and human neurons drive rapid, source-specific synaptic remodeling mediated by compartmental MAPK pathway activation. This neuronal co-culture model identifies distinct profiles of tumor-neuron communication, highlights synaptic vulnerability as a therapeutic axis, and demonstrates that MAPK pathway inhibition yields both neuroprotective and anti-tumor effects. SummaryGlioblastoma (GB) co-opts neuronal circuits to drive tumor progression, yet the earliest neuronal responses that may shape recurrence remain poorly defined. We developed a human iPSC-derived neuronal co-culture model that captures acute communication between neurons and glioblastoma from diverse sources, including serum-adapted cell lines and patient-derived cells. Within 24 hours, glioma-exposed neurons exhibited synaptic remodeling and activation of tumor-associated signaling pathways. High-resolution imaging and proteomics revealed compartment-specific synaptic alterations, with ERK1/2 and p38 MAPK signaling differentially engaged depending on the tumor source, corresponding to distinct structural and functional outcomes. Pharmacologic inhibition of MAPK components both suppressed tumor cells growth and preserved neuronal integrity. By modeling source-dependent and early neuron-tumor interactions, this platform not only identifies MAPK signaling as a critical mediator of synaptic vulnerability but also provides a clinically relevant tool for investigating the mechanisms of glioblastoma recurrence. It offers a framework for developing therapies that target the dual vulnerabilities of tumor progression and circuit remodeling. Highlights O_LIA dual-interface human iPSC-derived neuronal co-culture system models early neuron-glioblastoma (GB) interaction. C_LIO_LISerum-adapted U-87MG, but not serum-free patient-derived GB cells, induces pronounced synaptic disruption and neurite retraction. C_LIO_LIGlobal proteome of neurons reveals GB-associated signatures and neuronal circuit alterations in response to both U-87MG and patient-derived GB cells. C_LIO_LIERK1/2 and p38 MAPK signaling are differentially activated in neuronal compartments, depending on GB source. C_LIO_LIMAPK pathway inhibition suppresses U-87MG proliferation and preserves neuronal integrity, revealing actionable neuroprotective and anti-tumor targets. C_LI

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nebie, O., Adelakun, N., Zhang, L., Kollin, L., Fries, B., Medikonda, A., Venere, M., Giglio, P., Chu, N., Le, N. T.. 2025-09-16. A Human Neuronal Co-Culture System Reveals Early Tumor-Neuron Communication and Targetable Pathways in Glioblastoma. https://doi.org/10.1101/2025.09.10.675396

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sisyphus at the splenic flexure: sidedness in colorectal cancer

Colorectal cancer is divided into left and right to guide prognosis and therapy, yet a precise definition of left vs right sided colorectal cancer is still not fully agreed upon. The published conventions place it anywhere between the cecum and the rectosigmoid junction. The dichotomy assumes side homogeneity, i.e., that colorectal subsites within a side add limited information once the side is known. That assumption has been examined primarily through mutation prevalence, a quantity that confounds how often a driver arises with how strongly it is selected once it has. Analyzing 1,027 whole-exome and whole-genome sequenced colorectal tumors, we decomposed the prevalence of six driver groups into mutation supply and cancer effect, and asked whether a binary side label captures how each of their prevalence, mutation supply, and cancer effect vary along the colorectum. Mostly it does: the mutational input behaves as two blocks, and even the more than thirty-fold strengthening of cancer effect on BRAF V600E from sigmoid colon to cecum is adequately captured by side. But APC shows nominal evidence against side homogeneity in both prevalence and cancer effect while showing little net left-right difference, and PIK3CA H1047 rejects it in supply. The evidence for finer resolution is real but partial, and the failures do not announce themselves. We recommend additional research recording primary tumor location at the finest practicable resolution--at minimum, International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) topography. Such well-annotated datasets would enable the left-right boundary to be a reversible analytic choice rather than an irreversible annotation.

cancer biology↗

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

cancer biology↗

SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma

Glioblastoma is an incurable brain tumour characterised by extensive hypoxia and phenotypic plasticity, both of which drive therapy resistance. Mitochondrial glutathione, dependent on the inner membrane carrier SLC25A39, is central to buffering the oxidative stress that hypoxia generates; its regulation and significance in glioblastoma are nonetheless unknown. We find that SLC25A39 expression is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches and heterogeneously expressed within and between tumours. Its loss depletes mitochondrial glutathione, causing oxidative damage to nucleic acids and lipids, mitochondrial hyperfusion, impaired respiration and a compensatory shift towards glycolysis, glutamine catabolism and serine synthesis. SLC25A39-deficient cells grow poorly, yet resist temozolomide while becoming markedly sensitive to navitoclax, an inhibitor of Bcl-2 and Bcl-xL, which increases cell killing when combined with radiation and temozolomide. In this work, we identify SLC25A39 as a metabolic vulnerability and candidate stratification marker in glioblastoma.

cancer biology↗